Board Meeting Outcome for Audited Financial Results And Recommendation Of Final Dividend For Financial Year 2025-26
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported strong FY2026 consolidated results with revenue growing 37% to Rs. 2,02,299 lakhs from Rs. 1,47,684 lakhs in FY2025. Profit after tax jumped 40% to Rs. 36,400 lakhs, while EPS increased from Rs. 202.74 to Rs. 283.71. The company generated robust operating cash flows of Rs. 34,668 lakhs despite higher working capital requirements due to business growth. EBITDA margin expanded significantly from 18.3% to 24.2%. The board recommended a final dividend of Rs. 34 per share (340%). The statutory auditor issued an unmodified (clean) opinion on the financials. The company also announced a Rs. 143.4 crore capacity expansion at its Unit 1 in Telangana to address growing customer demand, with completion expected in 12-18 months.
The results show robust growth driven by strong performance across Europe and North America markets. The clean audit opinion and dividend declaration are positive signals for shareholders. The capacity expansion investment indicates management confidence in sustained demand growth.